Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Current Deferred Revenue (2016 - 2024)

Historic Current Deferred Revenue for Ascendis Pharma A (ASND) over the last 13 years, with Q4 2024 value amounting to $1.0 million.

  • Ascendis Pharma A's Current Deferred Revenue fell 2148.56% to $1.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.0 million, marking a year-over-year decrease of 2148.56%. This contributed to the annual value of $1.0 million for FY2024, which is 2047.58% down from last year.
  • According to the latest figures from Q4 2024, Ascendis Pharma A's Current Deferred Revenue is $1.0 million, which was down 2148.56% from -$600726.1 recorded in Q3 2024.
  • Ascendis Pharma A's 5-year Current Deferred Revenue high stood at $10.8 million for Q3 2022, and its period low was -$10.1 million during Q3 2023.
  • Over the past 5 years, Ascendis Pharma A's median Current Deferred Revenue value was -$579356.0 (recorded in 2020), while the average stood at -$158360.1.
  • Examining YoY changes over the last 5 years, Ascendis Pharma A's Current Deferred Revenue showed a top increase of 290472.05% in 2022 and a maximum decrease of 189576.43% in 2022.
  • Quarter analysis of 5 years shows Ascendis Pharma A's Current Deferred Revenue stood at -$590183.5 in 2020, then skyrocketed by 1108.32% to $6.0 million in 2021, then surged by 48.26% to $8.8 million in 2022, then crashed by 85.56% to $1.3 million in 2023, then decreased by 21.49% to $1.0 million in 2024.
  • Its Current Deferred Revenue stands at $1.0 million for Q4 2024, versus -$600726.1 for Q3 2024 and -$904585.6 for Q2 2024.